Theratechnologies (NASDAQ:THTX) announced its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03), MarketWatch Earnings reports. Theratechnologies had a negative net margin of 28.20% and a negative return on equity of 81.13%.
NASDAQ THTX opened at $2.22 on Friday. Theratechnologies has a fifty-two week low of $1.33 and a fifty-two week high of $4.20. The stock has a market cap of $170.97 million, a price-to-earnings ratio of -9.25 and a beta of 1.46. The business has a fifty day moving average of $2.39 and a 200-day moving average of $2.23. The company has a quick ratio of 1.26, a current ratio of 1.92 and a debt-to-equity ratio of 3.81.
Several research analysts have commented on THTX shares. Mackie reaffirmed a “buy” rating and set a $4.50 price target on shares of Theratechnologies in a research report on Friday. Canaccord Genuity restated a “buy” rating on shares of Theratechnologies in a research note on Monday, July 13th. Royal Bank of Canada restated a “hold” rating and issued a $2.00 price target on shares of Theratechnologies in a research note on Monday, July 20th. Echelon Wealth Partners reiterated a “buy” rating and set a $11.00 target price on shares of Theratechnologies in a research report on Wednesday, July 8th. Finally, Zacks Investment Research upgraded Theratechnologies from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Theratechnologies presently has an average rating of “Buy” and an average target price of $6.15.
Theratechnologies Company Profile
Theratechnologies Inc, a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients.
Featured Story: What causes a yield curve to invert?
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.